Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 128

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 128
---
 Mr. Serlin is a certified public accountant and holds a B. Sc.
degree in accounting from Yeshiva University and a Master’s degree in economics and public policy from The George Washington University.

Mali Zeevi, CPA, has served
as our Chief Financial Officer since October 2016. Prior to becoming Chief Financial Officer, Ms. Zeevi served as our Senior Director
of Finance and Reporting beginning in 2011 and as our Director of Finance and Reporting beginning in 2009. Before
joining BioLineRx, Ms. Zeevi was employed by Tescom Software Systems Testing Ltd., her last position there being Vice President Finance.
Ms. Zeevi also served as a certified public accountant at Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International
Limited. Ms. Zeevi is a certified public accountant and holds a B. A. degree in business and accountancy from the College of Management
Academic Studies in Israel.

Ella Sorani, Ph. D., has
served as our Chief Development Officer since January 2021. From February 2017 to December 2020, Dr. Sorani served as our Vice President
Research and Development. Before joining BioLineRx, from 2000 through 2016, Dr. Sorani served in a number of management positions in the
global R& D division at Teva Pharmaceutical Industries Ltd. In her most recent position as Senior Director and Global Project
Leader, Dr. Sorani led the development of one of Teva’s leading innovative late-stage compounds. Dr. Sorani holds a B. Sc. degree
in chemistry and an M. Sc. degree and Ph. D. in pharmacology, all from Tel Aviv University.

71

Aharon Schwartz, Ph. D., has served as the Chairman of our board of directors since 2004. Dr. Schwartz served in a number of positions at Teva from 1975 through
2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently a member of the board
of directors of Protalix Ltd. (NYSE American:PLX). Dr. Schwartz also works as an independent consultant. Dr. Schwartz received his Ph. D.
in organic chemistry from the Weizmann Institute of Science, an M. Sc. degree in organic chemistry from the Technion - Institute
of Technology and a B. Sc. degree in chemistry and